Advancements in Personalized Cellular Immunotherapy

• Offers an in-depth exploration of cellular immunotherapy, covering foundational principles, mechanisms of action, and clinical applications for both beginners and advanced professionals
• Illustrates the application of cellular immunotherapy, enhancing theoretical understanding and facilitating evidence-based clinical decision-making
• Discusses emerging trends, future directions, and challenges in cellular immunotherapy, including resistance mechanisms, treatment accessibility, and personalized medicine

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.

Dr. Murali Yallapu is a tenured Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology,Toxicology and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews. His current research primarily focuses on the development of nanomaterials for improved therapeutic potential of clinical drug(s) and developing new constructs for biomedical applications. Additionally, through Cancer Immunology Institute, he is working to generate safe and effective nanoformulations for cancer immunotherapy.

Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical Journal

Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.